OncoPharm

Sodium thiosulfate is now FDA-approved to minimize the risk of ototoxicity in some children receiving cisplatin.

Selpercatinib is granted a 'regular' approval for RET-fusion (+) NSCLC and an accelerated approval for other solid tumors.

Happy 9,22 day!

ESMO 2022 is wrapped and two studies in particular have caught our eyes:

NICHE-2: neoadjuvant Nivo/Ipi in MMR-d colon cancer

CODEBREAK: sotorasib vs. docetaxel

Updates on billiary track cancer - a role for durvalumab?

And pemigatinib - an approval in r/r myeloid/lymphoid neoplasms.

Plus, an oral suspension of ibrutinib is approved and more evidence ICI combination should be given early in BRAF-mutated metastatic melanoma (rather than waiting until disease progression on TKIs)

The Landmarks of OncoPharm series return to discuss the now standard-of-care temozolomide + RT for glioblastoma multiforme (GBM)

Stupp et al: https://www.nejm.org/doi/full/10.1056/NEJMoa043330

Effect of MGMT (the gene, not the band) on temozolomide effect (from the same NEJM issue) referenced, thought not discussed in this episode: https://www.nejm.org/doi/full/10.1056/NEJMoa043331

Dr. Amir Ali joins the Pod to cover the Foundations of OncoPharm on asparaginase products

In light of trastuzumab deruxtecan's approval for HER-mutated NSCLC, it's worthwhile to look back at the history of HER-targeted therapy in NSCLC and why/how targeted HER-mutated disease will affect practice.

New OS data is out for adjuvant atezolizumab in NSCLC - how does it compare to the original DFS data?

Plus, lots of recent FDA expanded approvals to discuss.

An infamous study that led to a drug approval of limited benefit, but still made its way into an episode of Better Call Saul.

Erlotinib + gemcitabine vs. gemcitabine: https://doi.org/10.1200/jco.2006.07.9525

Several recent large trials just released long term follow-up results on overall survival. We look at what how treatment principles may change based on these mature data.

ECHELON-1 - Hodgkin's (A+AVD vs. ABVD)

POLO - Pancreatic (olaparib maintenance vs. placebo)

Keynote 355 - mTNBC (pembrolizumab + chemo vs. chemo)

APHinity - adjuvant HER+ breast (pertuzumab/trastuzumab vs. trastuzumab)

E1912 - CLL (ibrutinib/rituximab vs. FCR)